The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.
Daratumumab (Darzalex) significantly improved progression-free survival when added to bortezomib (Velcade) and dexamethasone for patients with relapsed or refractory multiple myeloma.
Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy.
David Reardon, MD, discusses the potential for immunotherapy in brain cancer, its immunogenicity, and what preliminary data have shown so far regarding checkpoint inhibition.
Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.
Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.
Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.
Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.
Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.
Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.